
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics is a promising clinical-stage company with a strong focus on precision medicine and a pipeline of advanced product candidates targeting precision oncology and genetic diseases. With promising progress in their various development programs and a planned enrollment update for a Phase 3 study by YE26, there is potential for high demand for the company’s products. Additionally, the recently reported financing and increased confidence in the success of their product candidates could lead to significant growth and a positive market outlook. However, potential concerns such as hyperglycemia and pediatric growth impairment may need to be addressed in future studies to fully realize the potential of their products.
Bears say
Relay Therapeutics is a precision medicine company with a promising pipeline of medicine candidates for oncology and genetic diseases. However, uncertainty remains around the safety and long-term efficacy of its lead drug, zovegalisib. While there is potential for expansion in the treatment of lymphatic malformations, competition and potential limitations in lesion reduction could limit its overall market potential. Furthermore, concerns regarding the tolerability and potential side effects of rival drug alpelisib could benefit Relay Therapeutics in the long run.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares